ADVERTISEMENT

404

Not Found

Is this what you were looking for?

tag drug safety developmental biology immunology ecology

Bugs as Drugs to Boost Cancer Therapy
Danielle Gerhard, PhD | Jan 18, 2024 | 7 min read
Bioengineered bacteria sneak past solid tumor defenses to guide CAR T cells’ attacks.
Guts and Glory
Anna Azvolinsky | Apr 1, 2016 | 9 min read
An open mind and collaborative spirit have taken Hans Clevers on a journey from medicine to developmental biology, gastroenterology, cancer, and stem cells.
An illustration of flowers in the shape of the female reproductive tract
Uterus Transplants Hit the Clinic
Jef Akst | Aug 1, 2021 | 10+ min read
With human research trials resulting in dozens of successful deliveries in the US and abroad, doctors move toward offering the surgery clinically, while working to learn all they can about uterine and transplant biology from the still-rare procedure.
Toward Preventing Transplant Rejection with Immunologically Matched Stem Cells
Ruth Williams | Sep 15, 2016 | 3 min read
Matching the immunological characteristics of donor retinal cells to those of the recipient can reduce the chance of rejection.
The Role of Mom’s Microbes During Pregnancy
Carolyn A. Thomson and Kathy D. McCoy | Aug 1, 2021 | 10+ min read
Bacteria in the gut influence the production of antibodies and themselves secrete metabolites. In a pregnant woman, these compounds may influence immune development of her fetus.
Monoclonal Antibodies Find Utility In Cell Biology
Ricki Lewis | Dec 11, 1994 | 10+ min read
But, just as antibodies are finding increasing utility in cell biology, a new Food and Drug Administration classification for those products with clinical utility may affect researchers' access to the important technology (see accompanying story). Monoclonal History MAbs were born in 1975, when Georges Kohler and Cesar Milstein at the Medical Research Council Laboratories in Cambridge, England, fused two types of cells to form a hy
Monoclonal Antibodies Find Utility In Cell Biology
Ricki Lewis | Dec 11, 1994 | 10+ min read
But, just as antibodies are finding increasing utility in cell biology, a new Food and Drug Administration classification for those products with clinical utility may affect researchers' access to the important technology (see accompanying story). Monoclonal History MAbs were born in 1975, when Georges Kohler and Cesar Milstein at the Medical Research Council Laboratories in Cambridge, England, fused two types of cells to form a hy
Mimicry Muses
Mary Beth Aberlin | Aug 1, 2015 | 2 min read
The animal world is full of clever solutions to bioengineering challenges.
How Orphan Drugs Became a Highly Profitable Industry
Diana Kwon | May 1, 2018 | 10+ min read
Government incentives, advances in technology, and an army of patient advocates have spun a successful market—but abuses of the system and exorbitant prices could cause a backlash.
Contributors
Catherine Offord | Apr 1, 2016 | 3 min read
Meet some of the people featured in the April 2016 issue of The Scientist.

Run a Search

ADVERTISEMENT